RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Historical Holders from Q4 2017 to Q3 2025

Symbol
RYTM on Nasdaq
Type / Class
Equity / COM
Shares outstanding
66.4M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
70.9M
Holdings value
$7.16B
% of all portfolios
0.01%
Grand Portfolio weight change
+0.001%
Number of holders
262
Number of buys
153
Number of sells
-98
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 8.9% $361M 5.6M Baker Bros. Advisors LP 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 8.7% $482M 5.56M RA Capital Management, L.P. 30 Jun 2025
VANGUARD GROUP INC 7.52% $505M 5M The Vanguard Group 30 Sep 2025
PERCEPTIVE ADVISORS LLC 6.8% $285M 4.42M Perceptive Advisors LLC 31 Mar 2025
BlackRock, Inc. 6.9% $281M 4.36M BlackRock, Inc. 31 Mar 2025
PRIMECAP MANAGEMENT CO/CA/ 6.42% -15.6% $431M -$62.1M 4.26M -12.6% PRIMECAP MANAGEMENT CO/CA/ 30 Sep 2025
GOLDMAN SACHS GROUP INC 3% $117M 1.82M THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024

Institutional Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 70.9M $7.16B +$449M $100.99 262
2025 Q2 66.5M $4.2B +$137M $63.19 225
2025 Q1 64.6M $3.42B -$18.8M $52.97 226
2024 Q4 64.9M $3.63B -$159M $55.98 202
2024 Q3 67.7M $3.55B -$85.9M $52.39 175
2024 Q2 69.3M $2.85B +$52.8M $41.06 164
2024 Q1 68M $2.95B +$55.4M $43.33 166
2023 Q4 66.7M $3.07B -$41.8M $45.97 167
2023 Q3 68.1M $1.56B +$58.5M $22.93 143
2023 Q2 66.2M $1.09B +$94.1M $16.49 116
2023 Q1 60.3M $1.08B -$49.1M $17.84 125
2022 Q4 62.4M $1.82B +$85.6M $29.12 116
2022 Q3 59.5M $1.45B +$426M $24.50 99
2022 Q2 45.9M $191M -$18.8M $4.15 82
2022 Q1 48.8M $563M +$4.69M $11.52 105
2021 Q4 48.4M $484M -$538K $9.98 94
2021 Q3 48M $626M +$2.43M $13.06 93
2021 Q2 42.6M $835M -$3.43M $19.58 101
2021 Q1 47.6M $1.01B +$147M $21.27 119
2020 Q4 40.5M $1.2B +$39.5M $29.73 114
2020 Q3 39.2M $851M -$43.7M $21.67 114
2020 Q2 41.2M $920M +$12M $22.30 89
2020 Q1 40.8M $621M -$34.2M $15.22 80
2019 Q4 42.4M $973M +$189M $22.96 89
2019 Q3 34.3M $741M +$64.8M $21.59 84
2019 Q2 31.3M $688M +$9.1M $22.00 83
2019 Q1 30.9M $846M -$21.9M $27.41 85
2018 Q4 31.7M $851M +$12.8M $26.88 73
2018 Q3 31.1M $908M +$2.06M $29.17 77
2018 Q2 31M $970M +$216M $31.26 84
2018 Q1 24.4M $406M -$5.86M $19.90 54
2017 Q4 21.6M $628M +$507M $29.06 65